{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:09:49Z","timestamp":1772136589842,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,3,3]],"date-time":"2015-03-03T00:00:00Z","timestamp":1425340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1038\/tpj.2015.5","type":"journal-article","created":{"date-parts":[[2015,3,3]],"date-time":"2015-03-03T06:39:19Z","timestamp":1425364759000},"page":"461-466","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Establishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosis"],"prefix":"10.1038","volume":"15","author":[{"given":"M","family":"Verbelen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D A","family":"Collier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J H","family":"MacCabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C M","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,3]]},"reference":[{"key":"BFtpj20155_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1185\/03007999709113338","volume":"14","author":"HY Meltzer","year":"1997","unstructured":"Meltzer HY . Treatment-resistant schizophrenia - the role of clozapine. Curr Med Res Opin 1997; 14: 1\u201320.","journal-title":"Curr Med Res Opin"},{"key":"BFtpj20155_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3371\/CSRP.6.3.5","volume":"6","author":"HY Meltzer","year":"2012","unstructured":"Meltzer HY . Clozapine: balancing safety with superior antipsychotic efficacy. Clin Schizophr Relat Psychoses 2012; 6: 134\u2013144.","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"BFtpj20155_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1503\/jpn.100055","volume":"35","author":"R Joober","year":"2010","unstructured":"Joober R, Boksa P . Clozapine: a distinct, poorly understood and under-used molecule. J Psychiatry Neurosci 2010; 35: 147.","journal-title":"J Psychiatry Neurosci"},{"key":"BFtpj20155_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","volume":"60","author":"HY Meltzer","year":"2003","unstructured":"Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A et al. Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (InterSePT). Arch Gen Psychiatry 2003; 60: 82\u201391.","journal-title":"Arch Gen Psychiatry"},{"key":"BFtpj20155_CR5","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.schres.2013.07.043","volume":"150","author":"M Kiviniemi","year":"2013","unstructured":"Kiviniemi M, Suvisaari J, Koivumaa-Honkanen H, Hakkinen U, Isohanni M, Hakko H . Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5-year follow-up. Schizophr Res 2013; 150: 274\u2013280.","journal-title":"Schizophr Res"},{"key":"BFtpj20155_CR6","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/pds.3567","volume":"23","author":"G Ringback Weitoft","year":"2014","unstructured":"Ringback Weitoft G, Berglund M, Lindstrom EA, Nilsson M, Salmi P, Rosen M . Mortality, attempted suicide, re-hospitalisation and prescription refill for clozapine and other antipsychotics in Sweden - a register-based study. Pharmacoepidemiol Drug Saf 2014; 23: 290\u2013298.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"BFtpj20155_CR7","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.schres.2013.09.001","volume":"150","author":"J Reutfors","year":"2013","unstructured":"Reutfors J, Bahmanyar S, Jonsson EG, Brandt L, Boden R, Ekbom A et al. Medication and suicide risk in schizophrenia: a nested case-control study. Schizophr Res 2013; 150: 416\u2013420.","journal-title":"Schizophr Res"},{"key":"BFtpj20155_CR8","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","volume":"374","author":"J Tiihonen","year":"2009","unstructured":"Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374: 620\u2013627.","journal-title":"Lancet"},{"key":"BFtpj20155_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/BF00606409","volume":"11","author":"J Id\u00e4np\u00e4\u00e4n-Heikkil\u00e4","year":"1977","unstructured":"Id\u00e4np\u00e4\u00e4n-Heikkil\u00e4 J, Alhava E, Olkinuora M, Palva IP . Agranulocytosis during treatment with chlozapine. Eur J Clin Pharmacol 1977; 11: 193\u2013198.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFtpj20155_CR10","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H . Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789.","journal-title":"Arch Gen Psychiatry"},{"key":"BFtpj20155_CR11","unstructured":"Medicines and Healthcare Products Regulatory Agency Summary of Product Characteristics: Clozaril 100mg Tablets 2014. London, \n                    http:\/\/www.mhra.gov.uk\/home\/groups\/spcpil\/documents\/spcpil\/con1405056917253.pdf\n                    \n                  ."},{"key":"BFtpj20155_CR12","unstructured":"U.S. Food and Drug Administration Clozaril Prescribing Information 2013. U.S. Food and Drug Administration: Silver Spring, \n                    http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/019758s069s071lbl.pdf\n                    \n                  ."},{"key":"BFtpj20155_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1471-244X-14-102","volume":"14","author":"S Warnez","year":"2014","unstructured":"Warnez S, Alessi-Severini S . Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry 2014; 14: 102.","journal-title":"BMC Psychiatry"},{"key":"BFtpj20155_CR14","unstructured":"European Agency for the Evaluation of Medicinal Products, Committed for Proprietary Medicinal Properties (CPMP). Summary information on referral opinion following arbitration pursuant to Article 30 of Council Directive 2001\/83\/EC for Leponex and associated names (international non-proprietary name (INN): clozapine): Background information and Annex III. London, 2002. Retrieved from \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Leponex_30\/WC500010966.pdf\n                    \n                  ."},{"key":"BFtpj20155_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11845-011-0782-5","volume":"181","author":"JP Bogers","year":"2012","unstructured":"Bogers JP, Cohen D, Schulte PF, van Dijk D, Bakker B . Clozapine-induced leukopenia: arguments for rechallenge. Ir J Med Sci 2012; 181: 155\u2013156.","journal-title":"Ir J Med Sci"},{"key":"BFtpj20155_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2165\/00023210-200721010-00003","volume":"21","author":"E Whiskey","year":"2007","unstructured":"Whiskey E, Taylor D . Restarting clozapine after neutropenia: evaluating the possibilities and practicalities. CNS Drugs 2007; 21: 25\u201335.","journal-title":"CNS Drugs"},{"key":"BFtpj20155_CR17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.schres.2011.10.014","volume":"134","author":"P Manu","year":"2012","unstructured":"Manu P, Sarpal D, Muir O, Kane JM, Correll CU . When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res 2012; 134: 180\u2013186.","journal-title":"Schizophr Res"},{"key":"BFtpj20155_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/cbm.313","volume":"9","author":"M Swinton","year":"1999","unstructured":"Swinton M, Ahmed A . Reasons for non-prescription of clozapine in treatment-resistant schizophrenia. Criminal Behaviour and Mental Health 1999; 9: 207\u2013214.","journal-title":"Criminal Behaviour and Mental Health"},{"issue":"Suppl 1","key":"BFtpj20155_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2165\/00002018-199200071-00007","volume":"7","author":"SL Gerson","year":"1992","unstructured":"Gerson SL, Meltzer H . Mechanisms of clozapine-induced agranulocytosis. Drug Saf 1992; 7 (Suppl 1): 17\u201325.","journal-title":"Drug Saf"},{"key":"BFtpj20155_CR20","first-page":"3","volume":"59","author":"G Honigfeld","year":"1997","unstructured":"Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J . Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1997; 59: 3\u20137.","journal-title":"J Clin Psychiatry"},{"key":"BFtpj20155_CR21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJM199307153290303","volume":"329","author":"JMJ Alvir","year":"1993","unstructured":"Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA . Clozapine-induced agranulocytosis-incidence and risk factors in the United States. N Engl J Med 1993; 329: 162\u2013167.","journal-title":"N Engl J Med"},{"key":"BFtpj20155_CR22","doi-asserted-by":"publisher","first-page":"837","DOI":"10.4088\/JCP.11m07244","volume":"73","author":"L Lahdelma","year":"2012","unstructured":"Lahdelma L, Appelberg B . Clozapine-induced agranulocytosis in Finland, 1982-2007: long-term monitoring of patients is still warranted. J Clin Psychiatry 2012; 73: 837\u2013842.","journal-title":"J Clin Psychiatry"},{"key":"BFtpj20155_CR23","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1192\/bjp.175.6.576","volume":"175","author":"J Munro","year":"1999","unstructured":"Munro J, O'Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R . Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry 1999; 175: 576\u2013580.","journal-title":"Br J Psychiatry"},{"key":"BFtpj20155_CR24","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1192\/bjp.169.4.483","volume":"169","author":"K Atkin","year":"1996","unstructured":"Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O'Sullivan D . Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 1996; 169: 483\u2013488.","journal-title":"Br J Psychiatry"},{"key":"BFtpj20155_CR25","unstructured":"Kumar V . Clozaril Monitoring Systems, Registry Data and Analyses (United States, United Kingdom, and Australia). Presentation, Novartis 2002, Accessed online on 15 September 2014 \n                    http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/03\/slides\/3959S1_02_C-Novartis-Kumar.ppt\n                    \n                  ."},{"key":"BFtpj20155_CR26","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.4088\/JCP.11r06977","volume":"73","author":"D Cohen","year":"2012","unstructured":"Cohen D, Bogers JP, van Dijk D, Bakker B, Schulte PF . Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry 2012; 73: 1307\u20131312.","journal-title":"J Clin Psychiatry"},{"key":"BFtpj20155_CR27","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2165\/00023210-199504060-00004","volume":"4","author":"AJ Mendelowitz","year":"1995","unstructured":"Mendelowitz AJ, Gerson SL, Alvir JMJ, Lieberman JA . Clozapine-induced agranulocytosis. CNS Drugs 1995; 4: 412\u2013421.","journal-title":"CNS Drugs"},{"key":"BFtpj20155_CR28","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2217\/fnl.14.23","volume":"9","author":"B Nair","year":"2014","unstructured":"Nair B, MacCabe JH . Making clozapine safer: current perspectives on improving its tolerability. Future Neurology 2014; 9: 313\u2013322.","journal-title":"Future Neurology"},{"key":"BFtpj20155_CR29","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s11920-011-0185-3","volume":"13","author":"NI Chowdhury","year":"2011","unstructured":"Chowdhury NI, Remington G, Kennedy JL . Genetics of antipsychotic-induced side effects and agranulocytosis. Curr Psychiatry Rep 2011; 13: 156\u2013165.","journal-title":"Curr Psychiatry Rep"},{"key":"BFtpj20155_CR30","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.2217\/14622416.9.8.1101","volume":"9","author":"C Opgen-Rhein","year":"2008","unstructured":"Opgen-Rhein C, Dettling M . Clozapine-induced agranulocytosis and its genetic determinants. Pharmacogenomics 2008; 9: 1101\u20131111.","journal-title":"Pharmacogenomics"},{"key":"BFtpj20155_CR31","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4088\/JCP.09m05527yel","volume":"72","author":"MC Athanasiou","year":"2011","unstructured":"Athanasiou MC, Dettling M, Cascorbi I, Mosyagin I, Salisbury BA, Pierz KA et al. Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry 2011; 72: 458\u2013463.","journal-title":"J Clin Psychiatry"},{"key":"BFtpj20155_CR32","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.2217\/pgs.13.182","volume":"14","author":"BW Spencer","year":"2013","unstructured":"Spencer BW, Prainsack B, Rujescu D, Giegling I, Collier DA, Gaughran F et al. Opening Pandora's box in the UK: a hypothetical pharmacogenetic test for clozapine. Pharmacogenomics 2013; 14: 1907\u20131914.","journal-title":"Pharmacogenomics"},{"key":"BFtpj20155_CR33","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1038\/ncomms5757","volume":"5","author":"JI Goldstein","year":"2014","unstructured":"Goldstein JI, Fredrik Jarskog L, Hilliard C, Alfirevic A, Duncan L, Fourches D et al. Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. Nat Commun 2014; 5: 4757.","journal-title":"Nat Commun"},{"issue":"Suppl 1","key":"BFtpj20155_CR34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/hup.917","volume":"23","author":"RJ Flanagan","year":"2008","unstructured":"Flanagan RJ, Dunk L . Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol 2008; 23 (Suppl 1): 27\u201341.","journal-title":"Hum Psychopharmacol"},{"key":"BFtpj20155_CR35","unstructured":"Medicines and Healthcare Products Regulatory Agency Summary of Product Characteristics: Largactil 25mg\/ml Solution for Injection 2014. London, Retrieved from \n                    http:\/\/www.mhra.gov.uk\/home\/groups\/spcpil\/documents\/spcpil\/con1391143096918.pdf\n                    \n                  ."},{"key":"BFtpj20155_CR36","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1161\/CIRCULATIONAHA.105.594929","volume":"115","author":"KH Zou","year":"2007","unstructured":"Zou KH, O'Malley AJ, Mauri L . Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation 2007; 115: 654\u2013657.","journal-title":"Circulation"},{"key":"BFtpj20155_CR37","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1056\/NEJMoa0706135","volume":"358","author":"S Mallal","year":"2008","unstructured":"Mallal S, Phillips E, Carosi G, Molina J-M, Workman C, Toma\u017ei\u010d J et al. HLA-B* 5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568\u2013579.","journal-title":"N Engl J Med"},{"key":"BFtpj20155_CR38","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.2217\/14622416.9.10.1543","volume":"9","author":"PB Ferrell","year":"2008","unstructured":"Ferrell PB, McLeod HL . Carbamazepine, HLA-B* 1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008; 9: 1543\u20131546.","journal-title":"Pharmacogenomics"},{"key":"BFtpj20155_CR39","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3389\/fgene.2014.00096","volume":"5","author":"B Almoguera","year":"2014","unstructured":"Almoguera B, Vazquez L, Connolly JJ, Bradfield J, Sleiman P, Keating B et al. Imputation of TPMT defective alleles for the identification of patients with high-risk phenotypes. Front Genet 2014; 5: 96.","journal-title":"Front Genet"},{"key":"BFtpj20155_CR40","unstructured":"CRESTAR. CRESTAR \u2013 development of pharmacogenomic biomarkers for schizophrenia. 2011. Accessed online on 21 May 2014 \n                    http:\/\/www.crestar-project.eu\/\n                    \n                  ."}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/tpj20155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/tpj20155","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/tpj20155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:47:33Z","timestamp":1684608453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj20155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,3]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["BFtpj20155"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2015.5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/010900","asserted-by":"object"}]},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,3]]},"assertion":[{"value":"23 September 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"David A Collier is a full time employee of Eli Lilly and Company Ltd, and a visiting Professor at King\u2019s College London. David A Collier also holds stock in Eli Lilly and Company. Moira Verbelen is funded by a studentship from the Medical Research Council and Eli Lilly and Company Ltd. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}